[{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"mRNA-based Regenerative Medicine","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Pantherna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Pantherna Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Pantherna Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Evaxion Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pantherna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pantherna Therapeutics \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Pantherna Therapeutics \/ Pantherna Therapeutics"},{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Wacker Chemie AG","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"PAN004","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Pantherna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pantherna Therapeutics \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Pantherna Therapeutics \/ Pantherna Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Pantherna Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Through the collaboration, company aims to focus on the clinical development of PAN004, which is being evaluated in the preclinical studies for the treatment of acute respiratory distress syndrome.

                          Brand Name : PAN004

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 07, 2024

                          Lead Product(s) : PAN004

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Recipient : Wacker Chemie AG

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          February 08, 2023

                          Lead Product(s) : mRNA-based Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Evaxion Biotech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the new agreement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will be combined to promote research on the generation of regenerative medicine programs for new target organ using a direct reprogramming approa...

                          Brand Name : PTXmRNAs

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 04, 2022

                          Lead Product(s) : mRNA-based Regenerative Medicine

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Astellas Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank